Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article covers research on NMN supplementation dosing. It is informational only and is not medical advice. Consult a qualified healthcare professional before starting, stopping, or changing any supplement regimen, especially if you have medical conditions or take prescription medications.

TL;DR

• Published human trials have tested NMN at 250–1000 mg/day. Most evidence clusters at 250–500 mg/day.
• The NAD+ raising effect appears to flatten above roughly 500–600 mg/day. Doses above that threshold are primarily a marketing choice, not a trial-supported one.
• Age changes the rationale for starting NMN, not the dose range. The same 300–500 mg window appears in trials across adults from their 40s through their 70s.
• Budget matters most for quality assurance: below about $30/month for a 300–500 mg/day dose, certificate-of-analysis mismatches are common enough to be a practical concern.
• Timing data is limited; morning dosing is consistent with most published protocols.
• Popular stacks (NMN + resveratrol, NMN + TMG) are based on metabolic plausibility, not head-to-head human trial data.

What the dosage question is actually asking

Most people searching “how much NMN should I take” are working through three questions at once: What is the minimum dose the trials support? Does being older or younger change the answer? And how much is too much to spend on a supplement that has no confirmed clinical outcome benefit yet?

This article works through those questions from what the trial literature actually tested — not from what supplement marketing claims.

What human trials have actually used

The dose range in published human trials is 250–1000 mg/day. The most useful dose-response data comes from Liao et al. 2023, which randomized 80 middle-aged adults to 300, 600, or 900 mg/day for 60 days. Blood NAD+ rose at all three doses, but the increment between 600 and 900 mg was notably smaller than between 300 and 600. That dose-response compression pattern is consistent with earlier NMN bioavailability studies and with what the NR trial literature has shown at comparable dose escalations.

Two other frequently cited trials used lower doses:

• Yoshino et al. 2021 (Washington University / Keio University collaboration): 25 postmenopausal women with prediabetes, 250 mg/day for 10 weeks. Associated with improved muscle insulin sensitivity.
• Igarashi et al. 2022 (Keio University): older adults at 250 mg/day for 12 weeks. Modest changes in walking speed and grip strength relative to placebo.

Neither trial tested whether a higher dose would have produced larger effects. What the Liao data suggests is that the 300–500 mg range captures most of the NAD+ raising that higher doses achieve, at lower cost and lower exposure uncertainty. Going above 600 mg/day puts you in a zone where you are spending more for dose escalation that the current trial evidence does not clearly support.

Does age change the dose recommendation?

Strictly from the trials: not in any clinically meaningful way. Published studies have not established different effective doses across age groups in any consistent manner. What age changes is the reasoning behind starting NMN at all.

Adults in their 30s: Most published trials enrolled adults 40–80, so the evidence base for 30-somethings is extrapolation from older populations. In your 30s, NAD+ has declined somewhat from its peak but not to the degree seen in the 50s and 60s. Starting NMN here is a long-horizon bet on the NAD+ thesis rather than a response to measurable deficit. The conservative starting point is 250 mg/day — the low end of the trial range, enough to raise blood NAD+ based on available data, without reaching the dose range where marginal benefit becomes increasingly uncertain.

Adults in their 40s: Cross-sectional data suggests NAD+ decline accelerates in this decade. Several published trials enrolled primarily 40–60-year-olds as their core population. A starting dose of 300–500 mg/day aligns with the most-studied dose range for the most-studied age bracket. Beginning at 300 mg/day, assessing tolerance and any subjective response over 8–12 weeks before deciding whether to continue is a reasonable approach.

Adults in their 50s and older: Most NMN RCTs enrolled adults 50+, making this the age bracket with the most directly applicable evidence. The Yoshino 250 mg trial, the Igarashi 250 mg trial, and the Liao 300–900 mg trial all enrolled populations in this range. The dose recommendation remains 300–500 mg/day — but you are now closer to the actual trial populations, which gives the dose extrapolation a firmer base. Going to 500 mg as a once-daily dose is defensible. Going above 600 mg is not supported by the available dose-response data for any age group.

The point across all three brackets: the trial-supported dose range is the same. Age tells you something about why to consider NMN; it does not tell you to take more of it.

Budget tiers and what each level actually gets you

Tier	Monthly cost at 300–500 mg/day	Notes
Below $30	Frequent CoA mismatches	Purity testing frequently does not match label claims; proceed cautiously
$40–80 (mid-range)	Evidence-linked brands	Third-party certificates of analysis available; best value range for most buyers
$80–200 (premium)	Packaging and brand premium	Some legitimate quality differentiation; returns diminish above $100
Japanese pharmaceutical-scale	$100–200+	Mitsubishi NMN, Shinkoso NMN; manufacturing credentials differ from US supplement industry

The practical test for any brand: does the seller publish a current certificate of analysis on their website, matching label claims for NMN content and purity? NMN is unstable in heat and humidity, which means storage and shipping conditions also affect final product quality — a variable the CoA cannot account for if the brand is opaque about packaging.

For US buyers in the mid-range: Renue By Science and ProHealth Longevity both have third-party testing documentation. iHerb carries several brands at mid-range pricing, including both US-produced and Japanese-imported options. For Japanese-manufactured NMN specifically, Mitsubishi NMN and Shinkoso NMN ship internationally through Japanese retailers — the manufacturing scale and regulatory context differ from the US supplement market, which some buyers weigh as a quality signal.

Timing: when to take NMN

Most published trials used morning dosing, either fasted or with food. There is no rigorous comparative data on morning versus evening, so any recommendation here is partly informed by trial protocol convention rather than head-to-head timing data.

Some practical considerations from current practice:

• Split dosing (e.g., 250 mg morning, 250 mg midday) appears in some clinical protocols but has minimal comparative data against once-daily dosing.
• Taking NMN with a small amount of dietary fat is sometimes recommended for absorption; the evidence for this specific practice is anecdotal rather than derived from any published trial.
• If integrating NMN into an existing supplement routine, morning with breakfast is most consistent with what the trials tested.

Stack examples and their evidence status

Three common stacking patterns, with an honest read on what each is grounded in:

NMN + resveratrol (or pterostilbene): The rationale comes from research suggesting that sirtuins — a class of enzymes implicated in aging biology — require NAD+ as a substrate and are activated by resveratrol. The idea is that NMN raises the NAD+ available to sirtuins while resveratrol increases sirtuin activity, producing a combined effect greater than either alone. In mouse studies, there is some supporting evidence. In humans, no published trial has tested this combination against either compound alone in a controlled design. The effect is plausible but remains preliminary in humans.

NMN + TMG (trimethylglycine): The metabolic argument is that NMN conversion consumes methyl groups, and supplementing TMG replenishes the methyl pool. Some practitioners recommend 500–1000 mg TMG per 500 mg NMN. This is a pathway-plausibility argument based on known biochemistry — not a result from any published human trial testing the combination. It may make metabolic sense; it has not been empirically validated as a combination.

NMN alone: The only option with actual published human trial data behind the specific thing being taken. If you want to assess NMN’s effect on your own markers, starting with NMN alone before adding other compounds gives you a cleaner signal — relevant because the effect sizes involved are modest and easily masked by confounders.

None of these stacks are proven protocols. They are calibrated bets on biological plausibility, with evidence strength ranging from “replicated in mice” to “not yet tested in humans in a controlled design.”

Side effects and who should speak to a clinician first

At trial doses, NMN’s tolerability record looks clean. Adverse events reported in RCTs have been mild and at rates comparable to placebo: occasional digestive upset, mild nausea at higher doses, rare headache. No serious adverse events attributed to NMN have been published from any completed trial.

That said, published trials excluded several populations. If you fall into any of these groups, a clinician conversation is warranted before starting:

• Anyone on active cancer treatment (NAD+ metabolism is involved in cellular processes with dual relevance to cancer biology; this is mechanism plausibility, not confirmed risk in either direction)
• Anyone on anticoagulants or immunosuppressants (no formal interaction data exists for NMN)
• Pregnant or breastfeeding individuals (no trial data in this population)
• Adults with active liver disease (NMN is metabolized hepatically)
• Adolescents and children (no trial data)

The trial’s clean safety track record only extends to the populations that were actually enrolled — which is the reason these caveats exist, not evidence of confirmed harm.

A practical decision framework on dose

For someone working through the dose decision:

1. Start at 250–300 mg/day regardless of age. This covers bioavailability and NAD+ raising based on what the trials tested at the low end.
2. Assess over 8–12 weeks. If tracking personal markers — resting heart rate, subjective energy, exercise recovery — establish a baseline before starting.
3. Consider 500 mg/day if you want to be at the center of the trial dosing range and cost is manageable. The evidence does not support going above 600 mg.
4. Set a defined trial period. Six months is a reasonable minimum before deciding to continue, adjust, or stop.
5. Revisit annually. The NMN evidence base is moving; what is preliminary in 2026 may be meaningfully clearer by 2028.

If you are still working through whether NMN or NR makes more sense for your situation, the trial-by-trial comparison of evidence quality, regulatory status, and cost structure is in NMN vs NR: What Human Trials Actually Compare.

---

Part of our supplement reviews series. See also: NMN Supplements and Japan: Hype vs Evidence, 5 Japanese Longevity Habits Backed by Research.